Clinical trial
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients…
NCT00452400 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00452400 |
|---|---|
| Title | Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD. |
| Official title | Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Treatment of Orally Inhaled BI 1744 CL (3 - 4 Doses) Delivered by the Respimat® Inhaler in Patients With COPD |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive, Asthma |
| Intervention type | Drug |
| Interventions | BI 1744CL |
| Enrollment | 409 |
| Start date | Mar 1, 2007 |
| Primary completion | Jan 1, 2008 |
| First posted | Mar 27, 2007 |
| Last update posted | Jun 27, 2014 |
| Countries | Canada, Germany, Netherlands, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: